Navigation Links
DiagnoCure announces fourth quarter 2008 and year-end results
Date:12/17/2008

QUEBEC CITY, Dec. 17 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services, today reported financial and operation results for the fourth quarter 2008 and fiscal year ended October 31, 2008. The Company announced a net loss of $3,568,321 or $0.09 per share for the fourth quarter ending October 31, 2008, and a net loss of $13,833,978 or $0.33 per share for the fiscal year. These results are substantially in line with Management expectations and reflect the pre-marketing, development, validation and launch of Previstage(TM) GCC, and the beginning of marketing and sales activities. At the end of the quarter, cash, short-term investments and long-term investments stood at $20,130,705.

Highlights of the Quarter

In August, after completing the development and validation of its new Previstage(TM) GCC Colorectal Cancer Test in its service laboratory in West Chester, PA, DiagnoCure Oncology Laboratories received the required regulatory CLIA certification to perform the test. Since then, physicians have started to order the test and results have been reported back to them. During the quarter, the GCC marker and the Previstage(TM) GCC test have been discussed in an article published in Expert Review and at two scientific meetings. The marketing efforts are progressing well.

Gen-Probe, DiagnoCure's partner for the PCA3 prostate cancer test, announced at its third quarter earnings conference call that the sales of its CE-marked Progensa(TM) PCA3 test had grown four-fold in Europe in comparison with the same quarter a year ago. The market penetration continues to expand in Europe and in the Middle East with over 30 sites now offering the PCA3 test. In this quarter, a new study was published in the November issue of the Journal of Urology, bringing the total to four articles published on PCA3 in that journal only in 2008. The
'/>"/>

SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
2. DiagnoCure to host Q2 2008 earnings conference call and webcast
3. DiagnoCure announces second quarter 2008 results
4. DiagnoCures GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
5. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
6. DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
7. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
8. DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... Webcast to Follow, ROCKVILLE, Md., Oct. 30 ... biopharmaceutical company focused on the development,and commercialization of ... announced it will release results for the,quarter ended ... before the,market opens. A full text copy of ...
... COLORBLENDS will,donate a portion of the proceeds ... collection to the Christopher and Dana Reeve Foundation,(CDRF), ... cures for spinal cord injury and improving the ... Forward collection, available from COLORBLENDS online and,through its ...
... with families in ... the MetroHealth NICU, CLEVELAND, Oct. 30 ... hopes to spend time with,their newborn baby. The NICU is designed to ... the mission of the,March of Dimes to find the answers that will ...
... City Council to Vote on Measure Thursday, WASHINGTON, ... fillings in your mouth are actually composed of 50% ... your dentist office,and currently is not. Councilwoman Blondell Reynolds ... Bill No. 040904 which ensures that patients are,given the ...
... , TUESDAY, Oct. 30 (HealthDay News) -- Quality of life ... locally advanced non-small cell lung cancer, U.S. researchers report. , ... tumor size along with other empirical data to predict how ... of life is a critical factor in determining survival," lead ...
... American College of Physicians (ACP) will publish "Peripheral Arterial ... Key Diseases Series, the book is designed to provide ... and treatment of peripheral arterial disease (PAD), a condition ... a buildup of plaque in the arteries that supply ...
Cached Medicine News:Health News:Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007 2Health News:COLORBLENDS to Donate Portion of Sales of Spring Forward Daffodil Blend to the Christopher and Dana Reeve Foundation 2Health News:Browns Wives Host Special Day at MetroHealth Medical Center to Support the Neonatal Intensive Care Unit 2Health News:Browns Wives Host Special Day at MetroHealth Medical Center to Support the Neonatal Intensive Care Unit 3Health News:A Patients Right to Know: 'Silver Fillings' are 50% Mercury 2Health News:Quality of Life Predicts Lung Cancer Survival 2
(Date:12/24/2014)...  Commonwealth Cornerstone Group (CCG) today announced the completion of ... to help fund the expansion and consolidation of healthcare services ... . PHN is the largest federally ... It is the largest employer in Sharon,s ... staff. Currently, PHN Sharon offers scattered services out ...
(Date:12/24/2014)...  Conkwest, Inc., the Natural Killer Cell Company ... (NK) cell-line platform, Neukoplast® (NK-92™) as an immuno-oncology ... NantWorks founder, physician scientist and biotechnology entrepreneur, has ... $48 million of the Company,s Class A Common ... be named Co-Chairman of the Conkwest Board of ...
(Date:12/24/2014)... PHILADELPHIA , Dec. 23, 2014 ... a medical device company focused on skin permeation, ... that Scott W. Hollander has been ... Mr. Hollander has more than 20 years of ... equipment industries, and most recently served as Vice ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... IRIDEX Corporation (Nasdaq: IRIX ) today announced the receipt of an ... No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent ... product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser ... The Adjustable ...
... Denmark , July 29 AdvanDx today ... a fast, 90 minutes protocol for its Yeast Traffic ... PNA FISH turn-around time from the original 2.5 hours ... 90 minutes to 30 minutes.  Clinical validation studies performed ...
Cached Medicine Technology:IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery 2IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery 3AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 3AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 4
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Inquire...
Medicine Products: